S2 Ep14: Navigating Systemic Therapies in Atopic Dermatitis
2024/07/01
再生時間： 6 分
ポッドキャスト

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

S2 Ep14: Navigating Systemic Therapies in Atopic Dermatitis

無料で聴く

ポッドキャストの詳細を見る

サマリー
James Song, MD, FAAD, chief medical officer and director of clinical research at Frontier Dermatology in Seattle, Washington, delves into the complexities and advancements in treating atopic dermatitis (AD). Song highlights the challenges of transitioning patients from topical to systemic therapies, emphasizing the need for timely conversations and patient comfort. He discusses the efficacy and rapid response of oral JAK inhibitors compared to biologics, while addressing safety concerns and the necessity for blood monitoring. Song also explores patient-specific factors in treatment choices, the importance of systemic therapy for moderate to severe cases, and the promise of emerging biologics targeting IL-31 and OX40 pathways. This episode is a comprehensive guide for dermatology clinicians navigating the evolving landscape of AD treatments.

続きを読む一部表示

あらすじ・解説

James Song, MD, FAAD, chief medical officer and director of clinical research at Frontier Dermatology in Seattle, Washington, delves into the complexities and advancements in treating atopic dermatitis (AD). Song highlights the challenges of transitioning patients from topical to systemic therapies, emphasizing the need for timely conversations and patient comfort. He discusses the efficacy and rapid response of oral JAK inhibitors compared to biologics, while addressing safety concerns and the necessity for blood monitoring. Song also explores patient-specific factors in treatment choices, the importance of systemic therapy for moderate to severe cases, and the promise of emerging biologics targeting IL-31 and OX40 pathways. This episode is a comprehensive guide for dermatology clinicians navigating the evolving landscape of AD treatments.

続きを読む一部表示